FASN and astrocytoma (excluding glioblastoma): Supporting the critical role of FASN in the carcinogenesis of brain tumors, a recent phase II clinical study of relapsed high-grade astrocytoma showed an objective response rate of 56%, complete response rate of 17%, plus partial response rate of 39% in patients receiving FASN inhibition in combination with bevacizumab [85].